Astra to Split Drug Production Along China-US Fault Lines

(Bloomberg) — AstraZeneca Plc is fleshing out plans for a manufacturing network that will independently supply drugs to major markets as the U.S. pushes to reduce the pharma industry’s reliance on China.

The UK drugmaker will make the same medicine at different facilities to serve various markets separately, Chief Executive Officer Pascal Soriot said in an interview from the sidelines of the Boao Forum for Asia.